Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 11/20 | 0.45 |
| ▸ | CNR2 | P34972 | 11/20 | 0.45 |
| ▸ | ABHD12 | Q8N2K0 | 2/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435763 | 1.00 | OPRM1 (0.56) | OPRM1ACE2CNR1CNR2ABHD12 | |
| SCHEMBL13234380 | 1.00 | OPRM1 (0.56) | OPRM1ACE2CNR1CNR2ABHD12 | |
| SCHEMBL13214097 | 1.00 | OPRM1 (0.56) | OPRM1ACE2CNR1CNR2ABHD12 | |
| SCHEMBL26258669 | 0.92 | OPRM1 (0.46) | OPRM1ACE2CNR1CNR2TRPM8 | |
| SCHEMBL19130864 | 0.83 | CNR1 (0.46) | OPRM1CNR1CNR2ABHD12ABHD6 | |
| SCHEMBL13214089 | 0.83 | OPRM1 (0.54) | OPRM1CNR1CNR2NR1I2LDHA | |
| SCHEMBL17345391 | 0.83 | OPRM1 (0.54) | OPRM1CNR1CNR2NR1I2LDHA | |
| SCHEMBL24703685 | 0.83 | OPRM1 (0.54) | OPRM1CNR1CNR2NR1I2LDHA | |
| SCHEMBL24462903 | 0.81 | OPRM1 (0.66) | OPRM1ACE2CNR1CNR2 | |
| SCHEMBL22411941 | 0.78 | CNR1 (0.57) | OPRM1ACE2CNR1CNR2ABHD12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320720-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS (US) | 2015-11-12 | — | — | US | disclosed |
| US-9084771-B2 | Methods and compositions for treating cancer | SUTTER WEST BAY HOSPITALS (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150150844-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER BAY HOSPITALS | 2015-06-04 | — | — | US | disclosed |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | OPRM1 525/4885ACE2 4355/4885CNR1 2/4885 |
| US-20150150844-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | OPRM1 525/4885ACE2 4355/4885CNR1 2/4885 |
| US-20150320720-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | OPRM1 525/4885ACE2 4355/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.